Symrise to acquire Futura Labs
This article was originally published in The Rose Sheet
Executive Summary
Fragrance supplier Symrise will acquire Futura Labs Group, a flavors and fragrances manufacturer in Egypt and the United Arab Emirates, under a deal announced Nov. 18 and expected to close in the first quarter of 2010. The purchase reflects Symrise's focus on emerging markets, strengthening its presence in North Africa and the Middle East, CEO Heinz-Jurgen Bertram notes. "Futura Labs has an attractive base of international and regional clients and adds valuable new products to our existing portfolio in this region. The transaction will enable us to expand our market share while at the same time leveraging synergies in sales and production," Bertram says. Futura Labs recorded $15.1 million in revenue in 2008, according to the release
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.